Conclusion – Pleural effusion is a marker of advanced disease. In our study, 20% of hospitalized patients died within 30 days and almost 50% within a year. Mortality tops within the first month in patients with pleural effusions related to organ failure, while patients with malignant pleural effusions have the worst long-term outcome.

What is the life expectancy of a person with pleural effusion?

Introduction – Malignant pleural effusion (MPE) is defined as the accumulation of a significant amount of exudate in the pleural space, accompanied by the presence of malignant cells or tumour tissue. MPE presents a severe medical condition which can result in breathlessness, pain, cachexia and reduced physical activity.

Epidemiological information is limited, but an estimated 50 000 new diagnoses of MPE are made in the UK each year, The incidence and associated healthcare costs of MPE are expected to rise due to an increase in the global cancer rate and advances in systemic therapy, the latter of which allow many patients to live longer,

The majority of MPE is caused by metastatic disease: most commonly lung cancer in men and breast cancer in women. These two cancers combined account for 50–65% of all MPE, Mesothelioma is the most common type of primary pleural tumour and is associated with MPE in more than 90% of cases,

• Despite the progress in cancer treatment, the management of MPE remains palliative, with median survival ranging from 3 to 12 months,
• Patients’ prognosis is highly variable and depends on several factors (primary cancer, stage, performance status and pleural fluid proteins).
• To this end, the LENT (pleural fluid lactate dehydrogenase, Eastern Cooperative Oncology Group performance score, neutrophil-to-lymphocyte ratio and tumour type) prognostic score was recently proposed as a tool for the accurate prediction of survival,

Although LENT has the potential to aid in the assessment of patients with MPE, it requires prospective validation. During the last decade, there has been significant progress in unravelling the pathophysiology of MPE, as well as its diagnostics, imaging and management.

• Expanding interest in this area has resulted in an increasing number of cutting-edge laboratory studies that have developed experimental models of MPE which shed light on the pathogenesis of the phenomenon and tested novel biological agents as potential treatment options,
• Advances in high-throughput techniques (proteomics, genomics) have triggered developments in the discovery of biomarkers for the disease.

The use of thoracic ultrasound (TUS) in everyday practice has enhanced the diagnosis of MPE and assisted in the refinement of pleural procedures, Additionally, clinical research in MPE has progressed and high-quality, suitably powered, randomised controlled trials have begun to provide a more robust evidence base for some of the treatment approaches in the field,

How long can you live with untreated pleural effusion?

Mortality of Hospitalized Patients with Pleural Effusions 1 Pulmonary, Critical Care Medicine, Yale University School of Medicine, USA 3 Interventional Program (IP), Yale University School of Medicine, USA Find articles by 1 Pulmonary, Critical Care Medicine, Yale University School of Medicine, USA 3 Interventional Program (IP), Yale University School of Medicine, USA Find articles by 2 Claude D.

Pepper Older Americans Independence Center at Yale, Program on Aging, Yale University School of Medicine, USA Find articles by 2 Claude D. Pepper Older Americans Independence Center at Yale, Program on Aging, Yale University School of Medicine, USA Find articles by 1 Pulmonary, Critical Care Medicine, Yale University School of Medicine, USA Find articles by This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Each year in the United States an estimated 1.5 million people develop pleural effusions and approximately 178,000 thoracenteses (12%) are performed. While it has been established that malignant effusions are associated with increased mortality, the association between mortality and all-cause pleural effusions in a medical population has not been previously evaluated.

1. Our objective was to evaluate associations between 30-day and 12-month all-cause mortality among patients with a pleural effusion.
2. All patients admitted to the medical service at Yale-New Haven Hospital during March 2011 were screened for pleural effusion.
3. Pleural effusions were documented by the attending radiologist and the medical record was reviewed for admitting diagnosis, severity of illness and whether a thoracenteses was performed.

The outcomes were 30-day and 12-month mortality after identification of the pleural effusion. One-hundred and four patients admitted to the medical service had pleural effusions documented by the attending radiologist. At 30-days, 15% of these patients had died and by 12-months mortality had increased to 32%.

Eleven (10.6%) of the 104 patients underwent a thoracenteses. Severity of illness and malignancy were associated with 30-day mortality. For 12-month mortality, associations were found with age, severity of illness, malignancy, and diagnosis of pulmonary disease. Although sample size precluded statistical significance with mortality, the hazard ratio for thoracenteses and 30-day mortality was protective, suggesting a possible short term survival benefit.

In hospitalized medical patients with a pleural effusion, age, severity of illness and malignancy or pulmonary disease were associated with higher 12-month mortality. Thoracenteses may provide a protective effect in the first 30 days, but larger studies are needed to detect a short-term survival benefit.

1. The presence of a pleural effusion indicates a high risk of death, with 15% of patients dying within 30 days and 32% dead within one-year of hospital admission.
2. Eywords: Pleural effusion, Thoracenteses, Mortality The reported incidence of pleural effusions varies widely by patient population.
3. Each year in the United States (U.S.), an estimated 1.5 million people a year develop pleural effusions.

The majority of these are caused by Congestive Heart Failure (CHF), pneumonia, malignancy, and pulmonary emboli, Approximately 178,000 thoracenteses are performed each year in the U.S. in an effort to assist with diagnosis or therapy, The American College of Radiology recommends routine preoperative and admission chest radiographs (CXR) for older patients with stable cardiopulmonary disease who have not had a recent chest radiograph, and for persons suspected of acute cardiopulmonary disease.

A CXR is useful in detecting the presence of pleural effusions. Pleural effusion volumes as low as 25 ml can be detected with erect posterior-anterior (PA) chest radiographs, whereas at least 175 ml is needed for detection with supine chest radiographs, Past research has revealed an association between pleural effusions and mortality in certain patient populations.

The largest prospective multicenter study evaluating the association between chest radiographs and 30-day mortality identified the presence of bilateral pleural effusions as the strongest independent predictor of mortality for patients admitted with community-acquired pneumonia (CAP).

The second strongest predictor of 30-day mortality in patients with CAP was the presence of a pleural effusion classified as moderate, large, or massive, Almost half of all patients with metastatic malignancies develop pleural effusions, Patients with Malignant Pleural Effusions (MPE) have life expectancies ranging from 3 to 12 months, depending on the type and stage of their primary malignancy.

Patients with MPE secondary to lung cancer have the shortest life expectancy, while patients with a MPE secondary to ovarian cancer have the longest life expectancy, The mortality in patients with pleural effusions not associated with malignancy or acute infections is less well established.

Preliminary data from our Interventional Pulmonary (IP) program at Yale-New Haven Hospital suggests a high 30-day and one-year mortality in patients who underwent thoracenteses for pleural population of patients specifically referred for thoracenteses, or if the population with pleural effusions in general has a high mortality.

In order to understand the impact of pleural effusion and thoracenteses, we performed a retrospective study to document the incidence of pleural effusions, number of thoracenteses, and the 30-day and 12-month mortality in a defined inpatient population.

All adult patients admitted to Yale-New Haven Hospital medical floors during March 2011 who had a CXR performed within 24 hours of admission were screened for evidence of pleural effusion. Yale-New Haven Hospital is an academic teaching center with over 1000 beds. We did not include patients who were admitted to the intensive care unit, the surgical services or who were post-operative.

Approval for this study was obtained by the Institutional Review Board at Yale University School of Medicine. A waiver of consent was obtained as only chart review was performed. All CXR reports were screened for the presence of a pleural effusion, as indicated by the attending radiologist.

If a patient had multiple CXRs during their admission, only the first report was screened. When a pleural effusion was documented on CXR, the corresponding medical record was reviewed to obtain information about patient demographics, reason for admission, data to calculate the acute physiology and chronic health evaluation score (APACHE II), comorbid conditions, routine labs, as well as if a thoracenteses was performed during that admission.

Two research assistants who underwent training and inter-rater reliability using a standard protocol for abstracting data performed chart review. We combined reasons for hospital admission into specific groups including cardiac, pulmonary, malignancy, kidney, and other, based on the primary reason for admission as documented in the medical record.

The majority of medicine patients in our hospital are referred to interventional pulmonary (IP) for thoracenteses when the procedure is deemed necessary by treating physicians. In patients who underwent thoracenteses, pleural effusions were determined to be transudative or exudative based on Light’s criteria,

The clinical etiologies of the pleural effusions were determined by a pulmonologist with standard criteria that has been used in previous studies, We tracked mortality up to one year following the admission using chart review and the National Death Index.

• In addition, we examined the 30-day and 12-month mortality of patients in our IP database that underwent a thoracenteses for mortality comparison.
• Descriptive statistics were calculated on patient demographics and important clinical variables and compared between persons receiving and not receiving thoracenteses.

The clinical variables included reason for admission and the presence of comorbidities. Continuous variables were compared with a t-test and dichotomous variables with a chi-square statistic. A Kaplan-Meier plot of 12-month all-cause mortality was created comparing the empirical survival curves of persons with and without thoracenteses.

• Multivariable Cox models with fixed covariates were fit for both 30-day and 12-month all-cause mortality.
• In addition to thoracenteses, covariates included age, APACHE II score, gender, and indicators of three distinct reasons for admission: kidney disease, pulmonary disease, and malignancy.
• The associations with the reasons for admission are interpreted referent to the group comprised of patients admitted for all other conditions, including cardiac disease.

All analyses were conducted using SAS V9.3 with p-values ≤ 0.05 indicating statistical significance. Details of our study population are presented in, During the month of March 2011, there were 1705 patients admitted to the medical service at Yale-New Haven Hospital.

Of these, 744 (43.6%), had admission CXRs performed. Pleural effusions were identified on 104 CXRs (14%). Of patients with pleural effusions, 11 underwent thoracenteses (10%). compares demographics and medical comorbidities in patients that did and did not have thoracenteses. The mean age of the patient population was 72.7 (16.5) years.

There were no significant differences in baseline demographics or reason for hospital admission between patients who underwent thoracenteses and those who did not undergo thoracenteses. Compared to other groups, patients admitted with kidney failure were less likely to have a thoracenteses performed when a pleural effusion was identified.

Cardiac diseases included myocardial infarction, coronary artery disease, congestive heart failure, arrhythmia and hypertension; Pulmonary diseases included chronic obstructive lung disease, pneumonia, pulmonary embolism and obstructive sleep apnea; Malignancy included lymphoma, leukemia, lung cancer; Kidney disease included acute kidney injury; Other diseases include infection (urinary tract, line infection, peritoneal abscess), neurologic disorders such as cerebrovascular accident, intracerebral hemorrhage, hypertensive encephalopathy; gastrointestinal diseases including acute liver failure, diarrhea, dysphagia; and others such as syncope, diabetes, lower extremity thrombus, polymyositis, fever not otherwise specified, and fluid overload.

Continuous variables were tested using Student’s t-test and dichotomous variables with the chi-square statistic. There were no significant differences among the covariates between patients with and without thoracenteses. reports data on the etiologies of the pleural effusions in patients who had a thoracenteses performed.

Nine patients underwent a unilateral thoracenteses and two patients had bilateral thoracenteses performed. Characteristics of Pleural Fluid in Patients Undergoing Thoracenteses (N=11).

is a Kaplan-Meier plot of the 12-month survival estimates stratified by whether patients received a thoracenteses. Within the first 30 days, the survival probabilities of those who received a thoracenteses are higher. However, survival probability of those with thoracenteses drops precipitously somewhere between 50 and 100 days, remaining lower for the duration.

• We speculate that this reflects a short-term relief of symptoms, but a higher long term mortality reflecting the clinical fact that those receiving thoracenteses tend to be more severely ill than those not receiving it.
• The overall survival difference of those who did or did not receive a thoracenteses is not statistically significant over one year.

Reports the multivariable Cox model results. The positive association between admission for cancer and 30-day mortality was statistically significant (hazard ratio, 6.9; 95% CI, 1.6–29.9), as was that of APACHE II score (HR 1.1; 95% CI, 1.01–1.2). For 12- month mortality, there were significant associations with admissions for cancer (HR, 5.3; 95% CI, 1.8–15.3), pulmonary disease (HR, 2.4; 95% CI, 1.1–5.6), increasing APACHE II score (HR, 1.1; 95% CI, 1.03–1.2) and increasing age in years (HR, 1.04; 95% CI, 1.004–1.07).

Although not significant for either outcome, the HR for death following thoracenteses changed from 0.51 (95% CI, 0.06 – 4.04) over 30 days to 1.34 (95% CI, 0.45 – 3.96) over 12-months. The shift from thoracenteses having a potentially protective association in the short term, to a potentially deleterious association in the longer term, is supported by the corresponding survival plots in,

A post-hoc power analysis revealed that our sample (N=104) was underpowered to detect a significant association between thoracenteses and either short term or long term mortality. We would have needed substantially higher rates of both short term and long term mortality than those observed (15% and 32%) to detect significant associations of the magnitude observed in our data.

We performed a retrospective chart review of all non-ICU medical admissions to Yale-New Haven Hospital during March 2011. Almost half of all patients admitted to the medical service received a CXR at the time of presentation. The prevalence of pleural effusions among patients who had a chest radiograph on admission was 14%.

Not surprisingly, factors associated with increased mortality at both 30-days and 12-months were severity of illness as captured by the APACHE II score and a diagnosis of cancer. However, the overall mortality of 15% at 30 days and 32% at one year is worthy of attention. This investigation was prompted by the mortality rate seen in patients who presented to our IP service for thoracenteses.

Preliminary data from our prospective database demonstrated 35% 30-day mortality in patients with MPE, a 26% mortality in patients with multiple benign etiologies, and a 7–14% mortality in patients with CHF, liver or kidney failure. It was recognized that patients with pleural effusions presenting for thoracenteses may be different from patients who develop pleural effusions but do not undergo thoracenteses.

Since our IP program only sees patients with effusions who require a thoracenteses, we had no data for comparison on patients with pleural effusions who were not referred for thoracenteses, prompting this study. Pleural effusions are present in a large number of patients and are encountered by many medical disciplines.

Whereas it is fairly well known that patients with malignant pleural effusions have a high mortality and poor prognosis, we don’t believe that physicians, in general, grasp the idea that nearly 1 in 6 patients who have a pleural effusion will die within one month of presentation, as shown by this retrospective analysis.

1. We demonstrated that 15% of patients with a pleural effusion were dead within 30 days of admission.
2. This increased to nearly 1 in 3 patients with a pleural effusion who were dead within 1 year of admission (31% of patients who did not undergo thoracenteses and 36% of those who did).
3. For perspective, a recent analysis of more than 28 million hospital admissions demonstrated a 3.1% mortality for adult patients with four or more chronic medical conditions and 1.9% with 0–1 chronic medical conditions,

A prior study of critically ill patients demonstrated a 31% hospital mortality if patients experienced one or more organ-system failures, The patients evaluated in our study had common medical problems and are likely representative of a typical inpatient population at a University hospital.

Our data demonstrated that 10% of patients in the general medical inpatient population with pleural effusions underwent thoracenteses. The literature suggests that 1.5 million pleural effusions are present in the U.S. each year and that 178,000 thoracenteses are performed, indicating that 11.8% of pleural effusions are evaluated by thoracenteses.

We therefore believe our population and its frequency of thoracenteses are representative of the general inpatient medical population with pleural disease. What does this mean for our medical patients? The etiology of pleural effusions varies and the overall mortality related to these effusions likely varies by the cause of the effusion, with malignant effusions portending a poorer prognosis than benign effusions.

However, the presence of a pleural effusion should call attention to the providing physician that the patient has a high 30-day and 1-year mortality. As noted above, the protective tendency with 30-day mortality exhibited by thoracenteses, and supported by the Kaplan-Meier plots, suggests that a larger scale study is needed to establish whether this protective association is statistically significant.

As mentioned previously our sample size of 104 was underpowered to detect an association between thoracenteses and mortality. We note that many clinical studies are observational and underpowered, due to the well-known logistical and clinical complications of conducting research among medically ill persons,

• The good news is that an adequately powered observational study in this population may confirm the benefit in short term mortality from thoracenteses suggested by these findings.
• This study has several limitations.
• It is a single site study, retrospectively performed over a one month period.
• There may be seasonal variations in pleural fluid development that may relate to the underlying etiology of the effusion.

We may have underestimated the numbers of effusions if a patient never received a chest radiograph that documented pleural effusion. An additional limitation is that the specific cause of death for these patients was not identified. For instance, a patient with an effusion due to pneumonia may have actually died from myocardial infarction or a trauma in the subsequent year.

Rather, our results suggest that persons with pleural effusions constitute a patient population that appears to be at considerable risk for death. Strengths of this study include the general applicability to a general inpatient medical population. We performed a systematic chart review and analyze a current gap in the current research that has focused previously on critically ill patients or those with malignancy and infection.

We reviewed a large number of admissions and CXRs performed. We propose that the presence of a pleural effusion identified may serve as a “red flag” for physicians caring for these patients, and that its presence may signify the need for a stronger alert signal in the medical records, just as lab abnormalities are highlighted when critical results are present.

The major novelty of this study is its provision of evidence-based information confirming that on average, the mere presence of a pleural effusion indicates considerable risk of both short and long term mortality. The majority of patients admitted to general medical services have conditions that may be associated with pleural effusions.

Many patients with pleural effusions die within 30-days of admission to the hospital, and nearly 1/3 are dead within one year. A higher level of aggressive medical therapy may be warranted for those patients who present with pleural effusions in order to decrease their potential risk of death.

1. Pleural effusions may serve as a marker of mortality in this patient population.
2. The authors acknowledge Tona Donlon for her assistance in performing chart review.
3. Funding No financial support for this study was received.K.
4. Araujo and T.
5. Murphy were supported by the National Institute on Aging through the Claude D.

Pepper Older Americans Independence Center (P30AG21342) at Yale University.1. Light RW. Pleural effusions. Med Clin North Am.2011; 95 :1055–1070.2. Owings MF, Kozak LJ. Ambulatory and inpatient procedures in the United States, 1996. Vital Health Stat.1998; 13 :1–119.3.

• Collins JD, Furmanski S, Steckel RJ, Snow HD.
• Minimum calcification demonstrable in pulmonary nodules.
• A roentgen pathology model.
• Radiology.1972; 105 :49–50.4.
• Hasley PB, Albaum MN, Li YH, Fuhrman CR, Britton CA, et al.
• Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia? Arch Intern Med.1996; 156 :2206–2212.5.

Shaw PH, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database of Systematic Reviews.2004 6. Antunes G, Neville E, Duffy J, Ali N, et al. Pleural Diseases Group, Standards of Care Committee. BTS guidelines for the management of malignant pleural effusions.

1. Thorax.2003; 58 (Suppl 2):ii29–ii38.7.
2. Light RW, Macgregor MI, Luchsinger PC, Ball WC., Jr Pleural effusions: the diagnostic separation of transudates and exudates.
3. Ann Intern Med.1972; 77 :507–513.8.
4. Puchalski JT, Argento AC, Murphy TE, Araujo KL, Oliva IB, et al.
5. Etiologies of bilateral pleural effusions.

Respir Med.2013; 107 :284–291.9. Puchalski JT, Argento AC, Murphy TE, Araujo KL, Pisani MA. The safety of thoracenteses in patients with uncorrected bleeding risk. Ann Am Thorac Soc.2013; 10 :336–341.10. Steiner CA, Friedman B. Hospital utilization, costs, and mortality for adults with multiple chronic conditions, Nationwide Inpatient Sample, 2009.

• Prev Chronic Dis.2013; 10 :E62.11.
• Naus WA, Draper EA, Wagner DP, Zimmerman JE.
• Prognosis in acute organ-system failure.
• Ann Surg.1985; 202 :685–693.12.
• Murphy TE, Van Ness PH, Araujo KL, Pisani MA.
• Bayesian time-series analysis of a repeated-measures poisson outcome with excess zeroes.
• Am J Epidemiol.2011; 174 :1230–1237.

: Mortality of Hospitalized Patients with Pleural Effusions

Can you fully recover from pleural effusion?

Pleural Effusion Risks – There are many risks to treating a pleural effusion. Some cases may be managed with medication alone and are very safe. Most people will recover from this within a couple of weeks. When you have to have surgery to correct this, then you will have more problems.

Some problems include pain, or discomfort. If you have severe complications from the surgery then you have pulmonary edema, or fluid in the lungs, a partially collapsed lung, infections, or bleeding. These serious complications are very rare, but in some instances, they do occur. Pleural effusions can be serious and even life-threatening in some cases.

Most of the time, you will be hospitalized and surgery may be necessary. The time that it will take to recover can be dependent on the size, severity, cause, and your overall health. You will have to stay in the hospital overnight, but you will feel back to normal, on average, between 2-4 weeks.

Is pleural effusion the last stage of cancer?

Abstract – Malignant pleural effusion (MPE) is a common and important clinical condition. A complication in many types of tumors, its presence indicates the onset of the terminal stages of cancer. Dyspnea is the most common symptom of MPE. The most common underlying tumors are lymphomas and cancers of the lung, breast and ovaries, which account for 75% of cases.

• The diagnosis of MPE can be established by the presence of malignant cells in the pleural fluid or tissue.
• Median survival in these patients ranges from 3 to 12 months, with the shortest survival period presenting in lung cancer patients.
• The aim of MPE therapeutic approaches should be effective treatment and a short hospital stay.

There are many different treatment options for patients who suffer from MPE, including serial thoracentesis, tube thoracostomy, pleurodesis, long term pleural catheter, pleuroperitoneal shunt, decortication, chemotherapy and radiotherapy. The choice of therapy is determined based on a patient’s clinical situation as well as the underlying disease.

Has anyone survived pleural effusion?

Discussion – We performed a multicenter prospective observational study and demonstrated that PEs carry significant morbidity and mortality. Among all clinical parameters studied, short-term mortality was associated in our study with increased age, bilateral effusions, APACHE II and SOFA scores, and a high Charlson comorbidity index.

• Long-term mortality was found associated with a high Charlson comorbidity index, APACHE II and SOFA scores, and the presence of malignant pleural effusion.
• Overall mortality in our study was 22, 6% at 1 month and 49, 4% at 1 year, similar to previous findings of Debiasi and colleagues (21% at 30 days and 51% at 1 year).

Kookolis and colleagues in a retrospective study reported overall mortality of 15% at 30 days and 32% in 1 year ( 9, 10 ). These findings taken together illustrate a significant burden of pleural effusions in patients needing hospitalization in pulmonary or in other departments.

APACHE II score ranging from 10 to 14 is found to be associated with 7–15% in-hospital mortality ( 13 ), Sofa score above 2 is related to an increased risk of in-hospital mortality ( 14 ), and Charlson comorbidity index above 5 is associated with 80% 10 year-mortality ( 15 ). In our study worse APACHE II and SOFA scores were significant predictors of both short-term and long-term mortality.

This was also demonstrated by Kookoolis et al. ( 9 ). On the other hand, a novel finding of our study is the association of the Charlson comorbidity index with mortality. Thus, our findings suggest that the occurrence of pleural effusion in an aged individual with already multiple comorbidities may lead to acute decompensation as demonstrated by clinical severity scores.

1. Therefore, these patients upon admission should be monitored closely.
2. Congestive heart failure (HF) is the most common cause of PE ( 16 ) however the prognostic role of HF-related effusions is not well-established.
3. In a prospective study of 100 patients, PE didn’t predict outcome or mortality during a 6-month follow-up ( 17 ).

Ercan and colleagues reported favorable survival (81% at 1 year, n = 151) when effusions were incidentally observed in transthoracic echocardiogram ( 18 ). However, recent prospective studies report high mortality at 1 year (near 50%), suggesting that HF-related PEs, especially large refractory cases requiring aspiration, have a poor prognosis ( 10, 11 ).

Regarding other benign etiologies, mortality rates are also high. Walker and colleagues reported that 25% of patients with liver failure die within 1 year ( 11 ). In a population-based study of 3.487 cirrhotic patients with PE requiring drainage, 30-day and 1-year mortality were 20.1 and 59.1%, respectively ( 19 ).

Mortality in PE associated with renal etiology is not well-studied, yet a study of a small cohort of 14 patients with renal failure showed 14 and 57% 30-days and 1-year mortality, respectively ( 10 ). We report here significant high mortality rates for all patients with organ failure (20–30% in 1 month and 50–60% in a year).

Malignant pleural effusion (MPE) affects almost 15% of patients with underlying malignancy and is associated with a poor life expectancy ( 20 ). Like other studies, we demonstrated that MPE is associated with high mortality rates; 22% at 30 days and 74% at 1 year. Regarding long-term outcomes, patients with MPE had the worse prognosis of all underlying etiologies.

Among MPEs we found bilateral distribution and high APACHE score, indicating acute but also chronic health decompensation, associated with worse outcomes. Given this poor outcome, prognostic tools are crucial to personalize treatment and avoid unnecessary interventions ( 6, 21 ).

• It has been documented that PEs are poor prognostic signs in patients with pulmonary infection, especially when they are large, bilateral, or associated with empyema ( 4, 22, 23 ).
• Mortality rates range from 1% in simple uncomplicated parapneumonic pleural effusions to 30% in empyema or even 50% in ICU patients ( 8, 24 – 26 ).

Our study shows a significant risk of death in hospitalized patients with pleural infection (13.3% at 30 days), however exudative effusions had a favorable prognosis as opposed to transudative effusions ( Table 6 ). It has been established that the presence of bilateral PEs in patients with community-acquired pneumonia is an independent predictor of 30-day mortality with a relative risk of 2.8 ( 22 ).

However, Debiasi and colleagues first reported the association between bilateral PEs of any etiology and mortality. They reported 1-month mortality rates of 17% for unilateral vs.36% for bilateral PEs, and 1-year mortality rates 47 and 69%, respectively ( 10 ). Similarly, Walker and colleagues reported 1-year mortality rates of 20 and 57% for unilateral vs.

bilateral effusions ( 11 ). In accordance with these findings, we reported 1-month mortality rates of 13.3% for unilateral vs.32% for bilateral effusions. At 1 year our rates increase to 45.5 and 53.4%, respectively. Bilateral PEs in our study reflect the increased mortality rates observed in heart, liver, kidney, or multi-organ failure patients.

1. Therefore, the presence of bilateral PE regardless of etiology predicts significant mortality.
2. We also report a possible negative association between thoracentesis and mortality at 30 days.
3. Ookoolis and colleagues first documented a protective role of thoracentesis in a retrospective cohort.
4. Existing guidelines don’t recommend thoracentesis in patients within a clinical context highly suspicious of transudative PE ( 27 ).

Our finding might be due to underlying exudative etiologies, necessitating thoracentesis more commonly than transudates, since in our study exudates as we already mentioned had a better prognosis than transudates. We may not make a conclusive comment regarding the significance of thoracentesis in the present study, since not all effusions were aspirated.

Further, undergoing thoracentesis may be a confounding signal reflecting the patient’s clinical status allowing a procedure or not. The same applies to CTPA that also showed a protective role since CTPA is usually performed in unilateral PEs in patients with lower clinical severity scores and underlying exudative etiologies (e.g., pulmonary embolism).

Inhomogeneous CT requirement for inclusion in this study might introduce recruitment and confirmation bias, with mode of CT selected dependent on clinical and laboratory subjects’ condition. Therefore, the clinical utility of each CT mode cannot be commented in our study.

1. We believe however that this method allowed us to include more compromised patients and to better quantify the pleural effusion.
2. To our knowledge, this study is the largest prospective study on mortality in hospitalized patients with PE regardless of etiology and thoracentesis or not.
3. Charlson comorbidity index, clinical severity scores, bilateral distribution, and malignancy reflect on mortality of PEs.

As to the limitations of our study, our cohort represents hospitalized patients thus our results cannot be generalized to an outpatient setting. The limited number of subjects that underwent thoracentesis did not allow effusion discrimination by Light’s criteria to be included in the multivariate analysis.

How fast can pleural effusion progress?

RAPIDLY PROGRESSIVE PLEURAL EFFUSIONS – A rapidly progressive pleural effusion in a healthy patient suggests parapneumonic effusion. The most likely organism is streptococcal.2 Explosive pleuritis is defined as a pleural effusion that increases in size in less than 24 hours.

• It was first described by Braman and Donat 3 in 1986 as an effusion that develops within hours of admission.
• In 2001, Sharma and Marrie 4 refined the definition as rapid development of pleural effusion involving more than 90% of the hemithorax within 24 hours, causing compression of pulmonary tissue and a mediastinal shift.

It is a medical emergency that requires prompt investigation and treatment with drainage and antibiotics. All reported cases of explosive pleuritis have been parapneumonic effusion. The organisms implicated in explosive pleuritis include gram-positive cocci such as Streptococcus pneumoniae, S pyogenes, other streptococci, staphylococci, and gram-negative cocci such as Neisseria meningitidis and Moraxella catarrhalis,

Can a pleural effusion be harmless?

Abstract – Benign pleural effusions are twice as common as malignant effusions and have diverse causes and manifestations, which often makes them a diagnostic challenge. Differentiating effusions as a transudate or exudate is the first, and often helpful, step in directing investigations for diagnosis and management.

• Congestive heart failure and hepatic hydrothorax are the commonest causes for a transudative effusion.
• Commonly exudative effusions are caused by infections or may be secondary to pulmonary embolism, drugs, collagen vascular diseases, or may follow cardiac surgery.
• This article gives an overview of the causes and management of common benign pleural effusions.

Copyright © 2013 Elsevier Inc. All rights reserved.

Should I be worried about pleural effusion?

Fluid around the lung (pleural effusion) is a potentially dangerous condition that can masquerade as something less worrisome. What may seem like chest pain or coughing due to a bad cold could actually have serious health ramifications. It’s not that rare, either.

More than 1.5 million people are diagnosed with pleural effusion in the United States each year. Pleural effusion occurs when fluid builds up in the space between the lung and the chest wall. This can happen for many different reasons, including pneumonia or complications from heart, liver, or kidney disease.

Another reason could be as a side effect from cancer. “One of the most common reasons pleural effusion develops is due to congestive heart failure,” says Jonathan Puchalski, MD, a pulmonologist at Yale Medicine.

How long can you live with stage 4 pleural effusion?

Abstract – Malignant pleural effusions (MPE) are a common terminal pathway for many cancers, with an estimated United States incidence of more than 150,000 cases per year. MPE is an aggressive disease with a uniformly fatal prognosis and a life expectancy of only 3 to 12 months.

• The development of an effective targeted therapy represents a pressing unmet need.
• This commentary focuses on how cellular and humoral components condition the pleural space as a tumor-promoting, wound-healing environment.
• Despite an abundance of potential antigen presenting and effector cells in the pleura, their physical isolation by the mesothelial barrier, the concentration of cytokines and chemokines driving the epithelial to mesenchymal transition (EMT) and M2 /Th-2 polarization, suppress tumor-specific immune effector responses.

We argue that local immune repolarization must precede either immune checkpoint or cellular therapy to successfully eradicate pleural tumor. We further hypothesize that, because of its cellular content, a repolarized pleural space will provide an effective immune environment for generation of systemic anti-tumor response.

How rare is pleural effusion?

What causes pleural effusion? – Pleural effusions are very common, with approximately 100,000 cases diagnosed in the United States each year, according to the National Cancer Institute, Depending on the cause, the excess fluid may be either protein-poor (transudative) or protein-rich (exudative).

Heart failure Pulmonary embolism Cirrhosis Post open heart surgery

Exudative (protein-rich fluid) pleural effusions are most commonly caused by:

Pneumonia Cancer Pulmonary embolism Kidney disease Inflammatory disease

Other less common causes of pleural effusion include:

Tuberculosis Autoimmune disease Bleeding (due to chest trauma) Chylothorax (due to trauma) Rare chest and abdominal infections Asbestos pleural effusion (due to exposure to asbestos) Meig’s syndrome (due to a benign ovarian tumor) Ovarian hyperstimulation syndrome

Certain medications, abdominal surgery and radiation therapy may also cause pleural effusions. Pleural effusion may occur with several types of cancer including lung cancer, breast cancer and lymphoma. In some cases, the fluid itself may be malignant (cancerous), or may be a direct result of chemotherapy,

Can pleural effusion cured by medication?

Medications – Medications may be used to treat pleural effusion depending on its cause and symptoms. Types of medications used may include:

Antibiotics if there is an infection Steroids and nonsteroidal anti-inflammatory drugs to relieve pain and reduce inflammation or swelling Diuretics to help the body get rid of extra fluid by increasing the amount of urine it makes Bronchodilators to widen the airways in the lungs and allow for more air flow

Is pleural effusion terminal?

A build-up of fluid in the space between the lungs and the chest wall is called a “pleural effusion.” This area of the body is called the pleural space. Pleura is another word for membrane. You have pleura surrounding your lungs and lining the inside of your chest.

What stage of cancer is pleural effusion?

Stage IV cancer also includes people who have a fluid collection around the lung (called a malignant pleural effusion) caused by the cancer. Stage IV NSCLC cannot be cured, but treatment can reduce pain, ease breathing, and extend and improve quality of life.

Does fluid on lungs mean end of life?

Heart and lungs are last The lungs begin to fill with fluids. Breathing is accompanied by a wet, crackling sound. Although alarming to hear, it is a normal part of the dying process. It does not appear to reflect pain or discomfort for the patient.

Does pleural effusion mean cancer has spread?

Diagram of pleural effusion Several diseases or medical conditions can cause fluid to build up around the lungs. These include:

heart failure a blood clot in the lung (called a pulmonary embolism) liver disease a lung infection (pneumonia) kidney disease

A malignant pleural effusion is caused by cancer cells spreading to the space between the pleural layers. Cancer cells cause the body to make too much pleural fluid, and they stop the fluid from draining properly. They can also block or change the flow of lymph fluid in the pleural cavity. The following cancers are more likely to cause pleural effusion:

lung cancer breast cancer mesothelioma non-Hodgkin lymphoma stomach cancer kidney cancer ovarian cancer colon cancer cancer of unknown primary

Pleural effusion may not cause any symptoms at first, or the symptoms may be mild. Symptoms of pleural effusion depend on how much fluid there is and how quickly it is collecting in the pleural cavity. Symptoms of pleural effusion may include:

shortness of breath a cough chest pain or a feeling of heaviness in the chest anxiety a fever (if the fluid becomes infected) A general feeling of discomfort or illness. “>malaise

Shortness of breath can get worse when you lie down, which can make it hard for you to sleep. You may get very tired and breathless when you try to exercise. When you can’t breathe very well, you may also be anxious and feel like you are being suffocated. Your healthcare team may use the following tests to diagnose pleural effusion:

a physical exam a chest x-ray an ultrasound of the chest a CT scan

Find out more about these tests and procedures, A thoracentesis is a procedure that drains extra fluid from around the lung. A hollow needle is inserted between the ribs into the pleural cavity. The needle is used to remove the fluid. The fluid removed from the pleural cavity during a thoracentesis is examined in a lab. This fluid can help your healthcare team identify the cause of the pleural effusion. There are 2 types of fluid. Transudate fluid is watery and light coloured. It has little or no protein and low levels of an enzyme called An enzyme that is involved in energy production in cells. LDH is normally found in the blood and other body tissues. Higher levels of LDH may indicate tissue damage or the presence of cancer cells. LDH may be used as a tumour marker or to monitor a person’s response to treatment for certain cancers. Also called lactic acid dehyrodgenase. “>lactate dehydrogenase (LDH), which is found in most of our body’s tissues. Transudate fluid is caused by organ failure, most often heart, liver or kidney failure, or a pulmonary embolism. Exudate fluid is thick and cloudy. It has high levels of protein and LDH. Exudate fluid is most often caused by a lung infection, a pulmonary embolism or cancer. Cancer cells may be found in the fluid. Looking at these cancer cells can help identify the type of cancer causing pleural effusion in people who don’t have a history of cancer. Blood and pus may also be found in the fluid that is removed. If there is blood in the fluid, it is most likely caused by cancer. If there is pus in the fluid, it is caused by a lung infection. Cell and tissue tests may also be done on the fluid to look for any genetic changes that may help identify the type of cancer or help with treatment decisions. Find out more about a thoracentesis, If you have been diagnosed with pleural effusion but do not have any symptoms, your healthcare team will follow you closely. If you start having symptoms or problems breathing, they will start treatment. Fluid often builds up again after it is removed, so you may need more than one treatment. You may be offered the following treatment options for pleural effusion. A thoracentesis may be used to drain extra fluid from around the lung. If you have shortness of breath, it will improve as soon as the extra fluid is removed. But the extra fluid may build up again. While a thoracentesis may be done again, it can cause scar tissue and fluid pockets in the pleura, and it can make it harder to remove the fluid if it is done too often. If fluid keeps building up in the lungs, your healthcare team may offer to place a tunnel catheter so that you can have treatment at home. This procedure is usually done in an outpatient clinic. A thin, soft silicone tube is placed inside the chest cavity through a small cut (incision) between the ribs under local The loss of some or all feeling or awareness. “>anesthesia, The tube is then tunnelled underneath the skin to come out through another small incision. The pleural fluid drains into a bottle at the end of the tube. When the fluid has stopped draining, a cap is placed on the end of the catheter and sterile waterproof tape is placed on top. Fluid is drained 2 or 3 times a week by a nurse at home or at a local health unit. When the pleural fluid dries up, the tube is removed. In the hospital, the doctor or surgeon may place a tube through an incision in the chest between the ribs and into the pleural cavity. The tube is left in place to drain the extra fluid that is causing the pleural effusion. A chest tube may be placed at the end of a video-assisted thoracoscopic surgery (VATS). VATS is a type of chest surgery done with a flexible tube (called a thoracoscope) that has a camera attached to the end. The thoracoscope is placed inside the chest cavity through an incision in the ribs. The surgeon uses the camera as a guide to look at the pleural cavity. Then the chest tube is put through the incision and into the pleural cavity where the fluid is collecting. The pleural fluid drains into a bottle at the end of the tube. A pleurodesis is done to stop a pleural effusion from coming back after it has been drained. A pleurodesis seals up the space between the 2 layers of the pleural lining surrounding the lungs. It uses a chemical called a sclerosing agent to irritate and scar the lining so that it sticks to the lung. The most commonly used sclerosing agent is talc. A pleurodesis is done using a VATS surgery for placing a chest tube after the surgeon has found and drained the pleural effusion. After the fluid has drained, a sclerosing agent is put into the tube, which is closed to keep the agent in the area where the fluid was removed. Once the pleural membrane is sealed, the tube is opened and drained. You may have to have the procedure done again to completely seal the layers of the pleura to stop the fluid from building up. Side effects of treatment will depend mainly on the type of surgery and your overall health. Tell your healthcare team if you have side effects that you think are from your chest tube or tunnel catheter. The sooner you tell them of any problems, the sooner they can suggest ways to help you deal with them. Surgery for pleural effusion may cause these side effects:

infection fever pain collection of pus in the pleural cavity (called empyema) a drainage tube that moves out of place

Your healthcare team will treat the cancer that has caused pleural effusion. The treatment you have will depend on the type of cancer. You may receive chemotherapy, targeted therapy, hormone therapy, radiation therapy or a combination of these treatments.

• If you have a chest tube or tunnel catheter, the amount of fluid draining from the tube is a good way to tell how well your cancer treatment is working.
• Talk to your healthcare team about the amount of fluid and what it means.
• Your healthcare team may prescribe different drugs depending on the causes and symptoms of the pleural effusion.

You may be given antibiotics if you have an infection. You may also be given steroids or nonsteroidal anti-inflammatory drugs (NSAIDs) to relieve pain and reduce inflammation, or swelling. Your healthcare team will suggest treatments to help you breathe easier.

Drugs that relax and widen the airways or tubes in the lungs are called bronchodilators. They can help you get more air into your lungs. A physiotherapist on your healthcare team will be able to teach you deep breathing exercises that may help with feeling short of breath. Your healthcare team will also check the oxygen levels in your blood.

If you have low levels, you may be given oxygen therapy to make sure you get enough oxygen if you have trouble breathing. You breathe the oxygen in through a mask over your nose and mouth or through tubes in your nostrils. Your healthcare team may offer opioids, a type of narcotic pain medicine to help with shortness of breath.

Wilson K, Cooke C. Patient Education Information Series: Chest Tube Thoracostomy, American Thoracic Society; 2012: https://www.thoracic.org/, Kheir F, Akulian J, & Gesthalter YB. Patient Education Information Series: Indwelling Tunneled Pleural Catheters, American Thoracic Society; 2019: https://www.thoracic.org/, Jany B, Welte T. Pleural effusion in adults-etiology, diagnosis, and treatment. Deutsches Arzteblatt International,2019: 116: 377-386. US National Library of Medicine. Medline Plus Medical Encyclopedia: Pleural Fluid Analysis, Bethesda, MD: US Department of Health and Human Service; 2021: https://medlineplus.gov/encyclopedia.html, Monday, January 24, 2022. Alberta Health Services, Alberta Provincial Lung Tumour Team. Management of Malignant Pleural Effusion, Edmonton: Alberta Health Services; 2014: https://www.albertahealthservices.ca/, Beaudoin S, Gonzalez AV. Evaluation of the patient with pleural effusion. Canadian Medical Association Journal,2018: 190:E291-295.

Is pleural effusion always stage 4?

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer in the United States. About 84% of all lung cancer cases are NSCLC. It’s also usually less aggressive than small-cell lung cancer (SCLC). Pleural effusion is a buildup of fluid around the lungs.

1. Several lung conditions and even injuries to your chest can cause pleural effusion.
2. When due to NSCLC, pleural effusion is associated with cancer spread and decreased survival odds.
3. But new research shows that, with aggressive treatment, people with NSCLC and pleural effusion might have a better outlook than was previously believed.

Pleural effusion is the buildup of fluid between the layers of membranes that line your lungs and the inside of your chest cavity. These membranes are called pleura. There’s always a small amount of fluid in the pleura that acts as a lubricant to help you take in and expel air.

shortness of breath coughcough that’s worse in certain positionsbeing unable to lie flatchest pressure chest pain

Doctors often check for pleural effusion during NSCLC diagnosis. Doctors can do a few different tests to check for pleural effusion. These tests include:

Chest X-ray: A chest X-ray can take images of the lungs to look for fluid buildup. Chest CT scan or ultrasound: An imaging test such as a chest CT scan or ultrasound can create detailed images of the lungs. Thoracentesis: Thoracentesis uses a needle between the ribs to remove a sample of fluid for examination in a lab. Thoracoscopy: A thoracoscopy uses tiny cameras to allow doctors to see and treat the effusion at the same time. You’ll be under general anesthesia during the procedure.

Pleural effusion can be a sign that NSCLC has spread beyond the original tumor location. People whose NSCLC is at a higher stage are more likely to experience pleural effusion. In many cases, the presence of pleural effusion at diagnosis means the NSCLC has already advanced to stage 4,

But this isn’t always true. Pleural effusion can sometimes be the first symptom of lung cancer. It can also be due to complications of lung cancer. To determine the exact stage of your cancer when pleural effusion is present, your doctor will need to identify the underlying cause of the pleural effusion.

If the underlying cause is NSCLC, meaning the pleural effusion contains cancer cells, the cancer is stage 4. If the underlying cause is something other than NSCLC, your stage will depend on factors such as tumor size and whether it has spread to your lymph nodes or surrounding tissues.

Doctors typically consider pleural effusion to be a sign of a poor outlook for people with NSCLC. But recent studies ( 1, 2 ) suggest that more aggressive treatment of NSCLC with pleural effusion can help improve the survival odds of people with otherwise minimal disease (when cancer hasn’t spread beyond the chest).

Your exact treatments will depend on other factors and when pleural effusion develops. Options generally include:

Thoracentesis: Doctors use this procedure both to diagnose and treat pleural effusion. Tube thoracostomy: In a thoracostomy, doctors insert a tube into your chest for a day or more to drain fluid. Catheter: Doctors can place a catheter into your chest to drain fluid. They may use this option when fluid drainage needs to be ongoing. Shunt: A shunt is a surgically inserted tube doctors use to move fluid from one area of your body to another. Chemotherapy: In some cases, treating NSCLC with chemotherapy is also the best treatment for pleural effusion.

Until recently, doctors didn’t consider people with NSCLC and pleural effusion as candidates for tumor removal surgeries, But research has found that surgery can benefit some people with NSCLC and pleural effusion after receiving standard care. A 2019 study found that surgery improved the survival rate for people with minimal disease, meaning cancer that hasn’t spread beyond their chest.

More research on this topic is still needed, but initial results are promising. Doctors typically consider pleural effusion a sign of advanced NSCLC, and the outlook can be challenging, Once NSCLC is in later stages, the 5-year survival rate is 8%, But survival rates are based on old data. That figure represents data collected between 2011 and 2017.

With advances in treatment, it’s likely that the current number is higher and will continue to rise. If you have pleural effusion and NSCLC, your doctor might talk with you about palliative care, Palliative care can help you manage your NSCLC. Palliative care isn’t the same as hospice, and it doesn’t mean your doctor expects you to die quickly.

What are the stages of pleural effusion?

Pathophysiology – The evolution of a parapneumonic pleural effusion, as shown in the image below, can be divided into 3 stages, including exudative, fibrinopurulent, and organization stages. Left pleural effusion developed 4 days after antibiotic treatment for pneumococcal pneumonia. Patient developed fever, left-sided chest pain, and increasing dyspnea. During thoracentesis, purulent pleural fluid was removed, and the Gram stain showed gram-positive diplococci. The culture confirmed this to be Streptococcus pneumoniae. During the exudative stage, sterile pleural fluid rapidly accumulates in the pleural space. The pleural fluid originates in the interstitial spaces of the lung and in the capillaries of the visceral pleura because of increased permeability. The pleural fluid has a low white blood cell (WBC) count and a relatively low LDH level. The pleural fluid glucose and pH levels are within the reference range. These effusions resolve with antibiotic therapy, and chest tube insertion is not required. This stage takes approximately 2-5 days from the onset of pneumonia. In the second stage, or fibrinopurulent stage, bacterial invasion of the pleural space occurs, with accumulation of polymorphonuclear leukocytes, bacteria, and cellular debris. A tendency toward loculation and septation exists, pleural fluid pH (< 7.20) and glucose levels are lower (< 60 mg/dL), and the LDH levels increase. At this stage, bacteriological stains and/or cultures of the pleural fluid can be positive for microorganisms. This stage takes approximately 5-10 days after pneumonia onset. In the last, or organization stage, fibroblasts grow into the exudates from both the visceral and parietal pleural surfaces, and they produce an inelastic membrane called a pleural peel. Pleural fluid is thick. In an untreated patient, pleural fluid may drain spontaneously through the chest wall (ie, empyema thoracis necessitatis). Empyema thoracis may arise without an associated pneumonic process, such as from esophageal perforation, trauma, a surgical procedure in the pleural space, or septicemia. This last stage may take 2-3 weeks to develop.

How many times can a pleural effusion be drained?

PLACEMENT OF AN INDWELLING PLEURAL CATHETER – Indwelling pleural catheters are currently used as palliative therapy for patients with recurrent malignant pleural effusion who suffer from respiratory distress due to rapid reaccumulation of pleural fluids that require multiple thoracentesis procedures.

An indwelling pleural catheter is contraindicated in patients with uncontrolled coagulopathy, multiloculated pleural effusions, or extensive malignancy in the skin.3 Other factors that need to be considered are the patient’s social circumstances: ie, the patient must be in a clean and safe environment and must have insurance coverage for the supplies.

Catheters are 66 cm long and 15.5F and are made of silicone rubber with fenestrations along the distal 24 cm. They have a one-way valve at the proximal end that allows fluids and air to go out but not in ( Figure 1 ).1 Several systems are commercially available in the United States.

1. FIGURE 1 Draining of a pleural effusion in the left hemithorax.
2. The indwelling pleural catheter is tunneled under the soft tissue and enters the thoracic cavity between the ribs.
3. Proximally, the catheter has a one-way valve and evacuates into a negative-pressure bottle.
4. The catheter is inserted and tunneled percutaneously with the patient under local anesthesia and conscious sedation ( Figure 2 ).

Insertion is a same-day outpatient procedure, and intermittent pleural fluid drainage can be done at home by a home heathcare provider or a trained family member.7 FIGURE 2 Tunneling the indwelling pleural catheter under the soft tissue of the chest wall before insertion in the pleural cavity.

The procedure can be performed at the bedside under sterile conditions. The site of the insertion is identified with thoracic ultrasonography. (A), The guide wire is inserted at the thoracic inlet area, then (b) the catheter is tunneled under the skin to the guide wire area for insertion. In a meta-analysis, insertion difficulties were reported in only 4% of cases, particularly in patients who underwent prior pleural interventions.

Spontaneous pleurodesis occurred in 45% of patients at a mean of 52 days after insertion.8 After catheter insertion, the pleural space should be drained three times a week. No more than 1,000 mL of fluid should be removed at a time—or less if drainage causes chest pain or cough secondary to trapped lung (see below).

When the drainage declines to 150 mL per session, the sessions can be reduced to twice a week. If the volume drops to less than 50 mL per session, imaging (computed tomography or bedside thoracic ultrasonography) is recommended to ensure the achievement of pleurodesis and to rule out catheter blockage.

A large multicenter randomized controlled trial 9 compared indwelling pleural catheter therapy and chest tube insertion with talc pleurodesis. Both procedures relieved symptoms for the first 42 days, and there was no significant difference in quality of life.

However, the median length of hospital stay was 4 days for the talc pleurodesis group compared with 0 days for the indwelling pleural catheter group. Twenty-two percent of the talc group required a further pleural procedure such as a video-assisted thoracic surgery or thoracoscopy, compared with 6% of the indwelling catheter group.

On the other hand, 36% of those in the indwelling catheter group experienced nonserious adverse events such as pleural infections that mandated outpatient oral antibiotic therapy, cellulitis, and catheter blockage, compared with 7% of the talc group.9 Symptomatic, inoperable trapped lung is another condition for which an indwelling pleural catheter is a reasonable strategy compared with pleurodesis.

• Trapped lung is a condition in which the lung fails to fully expand despite proper pleural fluid removal, creating a vacuum space between the parietal and visceral pleura ( Figure 3 ).
• FIGURE 3 Computed tomography of the chest demonstrates (A) left malignant pleural effusion secondary to adenocarcinoma of the lung, and (B) trapped lung (black arrow) after placement of an indwelling pleural catheter (white arrow) in the same patient.

Patients with trapped lung complain of severe dull or sharp pain during drainage of pleural fluids due to stretching of the visceral pleura against the intrathoracic vacuum space. Trapped lung can be detected objectively by using intrathoracic manometry while draining fluids, looking for more than a 20-cm H 2 O drop in the intrathoracic pressure.

• Radiographically, this may be identified as a pneumothorax ex vacuo 10 (ie, caused by inability of the lung to expand to fill the thoracic cavity after pleural fluid has been drained) and is not a procedure complication.
• Placement of an indwelling pleural catheter is the treatment of choice for trapped lung, since chemical pleurodesis is not feasible without the potential of parietal and visceral pleural apposition.

In a retrospective study of indwelling catheter placement for palliative symptom control, a catheter relieved symptoms, improved quality of life, and afforded a substantial increase in mobility.1, 11 In another multicenter pilot study, 12 rapid pleurodesis was achieved in 30 patients with recurrent malignant pleural effusion by combining chemical pleurodesis and indwelling catheter placement.

Both were done under direct vision with medical thoracoscopy. Pleurodesis succeeded in 92% of patients by day 8 after the procedure. The hospital stay was reduced to a mean of 2 days after the procedure. In the catheter group, fluids were drained three times in the first day after the procedure and twice a day on the second and third days.

Of the 30 patients in this study, 2 had fever, 1 needed to have the catheter replaced, and 1 contracted empyema.

What happens if pleural effusion doesn’t go away?

If the pleural effusion doesn’t get better, a catheter may be placed in the chest. This is a flexible tube that allows fluid to drain from the lungs. The catheter stays in the chest until the doctor removes it.

What happens if pleural effusion is not drained?

If the pleural effusion is not drained, it can lead to dyspnea and even empyema.

How do you slow down pleural effusion?

Treatment – You can have treatment to stop fluid from building up and help relieve symptoms. This treatment is called pleurodesis. It seals the space between the tissues covering the lung by using sterile talc to make them inflamed so they stick together.

Then there is no space for fluid to collect. You can have this done as an outpatient if you are well enough. But you might need to stay in hospital overnight if there is a lot of fluid to drain off. This can take some time and your nurses will want to keep an eye on you. This treatment doesn’t treat the cancer.

But it should make it easier for you to breathe afterwards. You can have this treatment again if it doesn’t work completely the first time.

Is pleural effusion always stage 4?

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer in the United States. About 84% of all lung cancer cases are NSCLC. It’s also usually less aggressive than small-cell lung cancer (SCLC). Pleural effusion is a buildup of fluid around the lungs.

• Several lung conditions and even injuries to your chest can cause pleural effusion.
• When due to NSCLC, pleural effusion is associated with cancer spread and decreased survival odds.
• But new research shows that, with aggressive treatment, people with NSCLC and pleural effusion might have a better outlook than was previously believed.

Pleural effusion is the buildup of fluid between the layers of membranes that line your lungs and the inside of your chest cavity. These membranes are called pleura. There’s always a small amount of fluid in the pleura that acts as a lubricant to help you take in and expel air.

shortness of breath coughcough that’s worse in certain positionsbeing unable to lie flatchest pressure chest pain

Doctors often check for pleural effusion during NSCLC diagnosis. Doctors can do a few different tests to check for pleural effusion. These tests include:

Chest X-ray: A chest X-ray can take images of the lungs to look for fluid buildup. Chest CT scan or ultrasound: An imaging test such as a chest CT scan or ultrasound can create detailed images of the lungs. Thoracentesis: Thoracentesis uses a needle between the ribs to remove a sample of fluid for examination in a lab. Thoracoscopy: A thoracoscopy uses tiny cameras to allow doctors to see and treat the effusion at the same time. You’ll be under general anesthesia during the procedure.

Pleural effusion can be a sign that NSCLC has spread beyond the original tumor location. People whose NSCLC is at a higher stage are more likely to experience pleural effusion. In many cases, the presence of pleural effusion at diagnosis means the NSCLC has already advanced to stage 4,

But this isn’t always true. Pleural effusion can sometimes be the first symptom of lung cancer. It can also be due to complications of lung cancer. To determine the exact stage of your cancer when pleural effusion is present, your doctor will need to identify the underlying cause of the pleural effusion.

If the underlying cause is NSCLC, meaning the pleural effusion contains cancer cells, the cancer is stage 4. If the underlying cause is something other than NSCLC, your stage will depend on factors such as tumor size and whether it has spread to your lymph nodes or surrounding tissues.

1. Doctors typically consider pleural effusion to be a sign of a poor outlook for people with NSCLC.
2. But recent studies ( 1, 2 ) suggest that more aggressive treatment of NSCLC with pleural effusion can help improve the survival odds of people with otherwise minimal disease (when cancer hasn’t spread beyond the chest).

Your exact treatments will depend on other factors and when pleural effusion develops. Options generally include:

Thoracentesis: Doctors use this procedure both to diagnose and treat pleural effusion. Tube thoracostomy: In a thoracostomy, doctors insert a tube into your chest for a day or more to drain fluid. Catheter: Doctors can place a catheter into your chest to drain fluid. They may use this option when fluid drainage needs to be ongoing. Shunt: A shunt is a surgically inserted tube doctors use to move fluid from one area of your body to another. Chemotherapy: In some cases, treating NSCLC with chemotherapy is also the best treatment for pleural effusion.

Until recently, doctors didn’t consider people with NSCLC and pleural effusion as candidates for tumor removal surgeries, But research has found that surgery can benefit some people with NSCLC and pleural effusion after receiving standard care. A 2019 study found that surgery improved the survival rate for people with minimal disease, meaning cancer that hasn’t spread beyond their chest.

• More research on this topic is still needed, but initial results are promising.
• Doctors typically consider pleural effusion a sign of advanced NSCLC, and the outlook can be challenging,
• Once NSCLC is in later stages, the 5-year survival rate is 8%,
• But survival rates are based on old data.
• That figure represents data collected between 2011 and 2017.

With advances in treatment, it’s likely that the current number is higher and will continue to rise. If you have pleural effusion and NSCLC, your doctor might talk with you about palliative care, Palliative care can help you manage your NSCLC. Palliative care isn’t the same as hospice, and it doesn’t mean your doctor expects you to die quickly.

Is pleural effusion stage 4?

Stage IV cancer also includes people who have a fluid collection around the lung (called a malignant pleural effusion) caused by the cancer. Stage IV NSCLC cannot be cured, but treatment can reduce pain, ease breathing, and extend and improve quality of life.

What is the stage of pleural effusion?

Pathophysiology – The evolution of a parapneumonic pleural effusion, as shown in the image below, can be divided into 3 stages, including exudative, fibrinopurulent, and organization stages. Left pleural effusion developed 4 days after antibiotic treatment for pneumococcal pneumonia. Patient developed fever, left-sided chest pain, and increasing dyspnea. During thoracentesis, purulent pleural fluid was removed, and the Gram stain showed gram-positive diplococci. The culture confirmed this to be Streptococcus pneumoniae. During the exudative stage, sterile pleural fluid rapidly accumulates in the pleural space. The pleural fluid originates in the interstitial spaces of the lung and in the capillaries of the visceral pleura because of increased permeability. The pleural fluid has a low white blood cell (WBC) count and a relatively low LDH level. The pleural fluid glucose and pH levels are within the reference range. These effusions resolve with antibiotic therapy, and chest tube insertion is not required. This stage takes approximately 2-5 days from the onset of pneumonia. In the second stage, or fibrinopurulent stage, bacterial invasion of the pleural space occurs, with accumulation of polymorphonuclear leukocytes, bacteria, and cellular debris. A tendency toward loculation and septation exists, pleural fluid pH (< 7.20) and glucose levels are lower (< 60 mg/dL), and the LDH levels increase. At this stage, bacteriological stains and/or cultures of the pleural fluid can be positive for microorganisms. This stage takes approximately 5-10 days after pneumonia onset. In the last, or organization stage, fibroblasts grow into the exudates from both the visceral and parietal pleural surfaces, and they produce an inelastic membrane called a pleural peel. Pleural fluid is thick. In an untreated patient, pleural fluid may drain spontaneously through the chest wall (ie, empyema thoracis necessitatis). Empyema thoracis may arise without an associated pneumonic process, such as from esophageal perforation, trauma, a surgical procedure in the pleural space, or septicemia. This last stage may take 2-3 weeks to develop.

Should I be worried about pleural effusion?

Fluid around the lung (pleural effusion) is a potentially dangerous condition that can masquerade as something less worrisome. What may seem like chest pain or coughing due to a bad cold could actually have serious health ramifications. It’s not that rare, either.

• More than 1.5 million people are diagnosed with pleural effusion in the United States each year.
• Pleural effusion occurs when fluid builds up in the space between the lung and the chest wall.
• This can happen for many different reasons, including pneumonia or complications from heart, liver, or kidney disease.

Another reason could be as a side effect from cancer. “One of the most common reasons pleural effusion develops is due to congestive heart failure,” says Jonathan Puchalski, MD, a pulmonologist at Yale Medicine.